Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 2/20 | 0.46 |
| ▸ | FNTB | P49356 | 2/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | FFAR3 | O14843 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | THPO | P40225 | 1/20 | 0.32 |
| ▸ | LCK | P06239 | 1/20 | 0.32 |
| ▸ | FYN | P06241 | 1/20 | 0.32 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.31 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.31 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.31 |
| ▸ | GRIK5 | Q16478 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL554290 | 0.86 | FNTA (0.54) | FNTAFNTBTHRBPGGT1BTDP1 | |
| SCHEMBL164727 | 0.86 | FNTA (0.54) | FNTAFNTBTHRBPGGT1BTDP1 | |
| SCHEMBL554287 | 0.86 | FNTA (0.54) | FNTAFNTBTHRBPGGT1BTDP1 | |
| SCHEMBL304615 | 0.83 | FNTA (0.52) | FNTAFNTBTHRBPGGT1BTDP1 | |
| SCHEMBL304617 | 0.83 | FNTA (0.52) | FNTAFNTBTHRBPGGT1BTDP1 | |
| SCHEMBL1300238 | 0.81 | FNTA (0.45) | FNTAFNTBTHRBPGGT1BTDP1 | |
| SCHEMBL2620527 | 0.80 | FFAR3 (0.42) | FNTAFNTBTHRBPGGT1BTDP1 | |
| SCHEMBL8852386 | 0.79 | FNTA (0.43) | FNTAFNTBTHRBPGGT1BTDP1 | |
| SCHEMBL732787 | 0.79 | FNTA (0.54) | FNTAFNTBTHRBPGGT1BTDP1 | |
| SCHEMBL30198647 | 0.78 | FNTA (0.41) | FNTAFNTBTHRBPGGT1BTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110263873-A1 | Enantioselective Synthesis of y-amino-alpha beta-unsaturated carboxylic acid derivatives | NOVARTIS AG (CH) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263873-A1 | Enantioselective Synthesis of y-amino-alpha beta-unsaturated carboxylic acid derivatives | BCAT1, BCAT2, AADAT | FNTA 769/4885FNTB 610/4885THRB 941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.